Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Participants With Tinea Pedis and Tinea Cruris

Exclusion Criteria

• •Female participants who are pregnant and/or nursing or planning a pregnancy during the course of the trial
• •Participants who are immunocompromised
• •Participants who have a recent history of or currently known drug or alcohol abuse
• •Participants with a history of intolerance or hypersensitivity to imidazole compounds, proton pump inhibitors, or the inactive components of luliconazole cream 1% or omeprazole
• •Participants with a life-threatening condition within the last 6 months
• •Participants with uncontrolled diabetes mellitus
• •Participants who are unable to communicate or cooperate with the Investigator
• •Participants using medications for treatment of tinea pedis and/or tinea cruris (see Investigator for length of time prior to study start)
• •Participants receiving concomitant drugs that are known to inhibit and/or induce CYP2C19 and/or CYP3A4, or that interact with omeprazole
• •Because of the potential for drug interaction with luliconazole, administration with medications that are known to be substrates of CYP3A4, CYP2B6, CYP2C8, and CYP2C19 should be carefully monitored